© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
May 09, 2022
Patients are at risk for developing severe dry eye and ocular surface disease.
May 06, 2022
A second FDA indication for the treatment of allergic conjunctivitis proves promising for patient relief.
March 17, 2022
Short-term steroid use can alleviate patient discomfort.
March 10, 2022
Equally important is that any symptoms of ocular allergies should be addressed to reduce the frequency of eye rubbing.
October 11, 2021
The FDA approved Ocular Therapeutix Inc.’s Supplemental New Drug Application (sNDA) that further extends Dextenza’s (dexamethasone ophthalmic insert) 0.4 mg indications, the company announced Monday.
August 12, 2021
Tool for quantifying measures may predict outcomes for patients.
August 09, 2021
Most patients with allergic disorder are children, adolescents, or young adults.
June 25, 2021
Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).
June 22, 2021
According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.
June 17, 2021
The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.